Navigation Links
Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
Date:10/3/2008

ional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding the development and commercialization of the T5000 Biosensor System, Ibis' technology, and the revenue potential of certain government contracts and grants. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward- looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, and its most recent quarterly report on Form 10- Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals is a r
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. SyntheMed Announces New Management Appointments
2. Alba Therapeutics Corporation Announces Promotions
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. 23andMe Announces Breast Cancer Initiative
5. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
6. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
7. Synthetech Announces New Director of Manufacturing
8. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
9. Biotel Announces Record Revenues and Earnings for Fiscal 2008
10. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
11. Helix BioPharma Announces $11.4 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YARDLEY , Pennsylvanie, 18 septembre 2014 ... Lyon en 1974, a été ... à compléter les évaluations cliniques traditionnelles par ... Reported Outcomes) et sur les impacts économiques ... http://photos.prnewswire.com/prnh/20140618/119365 A cours ...
(Date:9/18/2014)... OMICS Group International invites researchers, authors and academicians ... Access Week’ by actively contributing their research outcome ... from 20-26th October, 2014. , Pharmaceutical Sciences ... with a tremendous speed to provide improved medical ... is gearing with innovation and technological revolution to ...
(Date:9/18/2014)... a group of rare diseases that afflict skeletal ... onset hits at the fetal stage and is ... gene encoding fibroblast growth factor receptor 3 (FGFR3) ... dysplasia, thanatophoric dysplasia (TD), a skeletal dysplasia that ... often lethal, and achondroplasia (ACH), which causes stunted ...
(Date:9/18/2014)... Artificial sweeteners, promoted as aids to weight loss and ... intolerance and metabolic disease; and they do it in ... of the gut microbiota the substantial population of ... of experiments in mice and humans, were published today ... Eran Elinav of the Weizmann Institute,s Immunology Department, who ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... until further notice, RICHMOND, Va., Oct. 21 Insmed ... that on Thursday, October 16, 2008 NASDAQ issued a notice ... the enforcement of the rules ... Effective immediately, NASDAQ has also suspended the enforcement of the ...
... SAN DIEGO, Oct. 21 Althea Technologies, ... technologies for pharmaceutical,development and manufacturing, announced today ... as its President and Chief Executive Officer. ... Services (PDS) at,Patheon, Inc., will lead Althea,s ...
... Calif., Oct. 21 (11:00 PM PT,Oct. 20) ... announced that,Novartis AG has agreed to acquire from ... for $115 million in cash., "This agreement ... the development,of novel therapeutics using our PEGylation and ...
Cached Biology Technology:Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule 2Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule 3Althea Technologies Appoints Dr. Shabbir Anik as Chief Executive Officer 2Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 2Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 3Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder 4
(Date:9/18/2014)... matter how many times it,s demonstrated, it,s still ... , But by using a signaling system ... their behavior to suit their population. In short, ... present, and act accordingly. , Once the population ... change from innocuous to pathogenic, or from unhelpful ...
(Date:9/18/2014)... Sept. 18, 2014 -- Arizona turned its newborn screening program ... few short months, earning it the first-ever Newborn Screening Quality ... of Dimes presented Will Humble, M.P.H., Arizona,s Department of Health ... today. Mr. Humble established a policy of full transparency for ... newborn blood samples to the lab for analysis, and set ...
(Date:9/18/2014)... global cycles of carbon and nitrogen comprise all ... and environmental systems have caused imbalances and perturbations ... gases (GHGs). Increased GHGs result in climate changes ... ecosystems, oceans and the atmosphere. Understanding these feedback ... branch of environmental science during the past three ...
Breaking Biology News(10 mins):Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Greenhouse gas research enters a new era 2
... NJIT Distinguished Professor Philip R. Goode and the Big Bear ... a deformable mirror in what is called adaptive optics ... an image of a sunspot was published yesterday on the ... day: http://www.cieletespace.fr/node/5752 "This photo ...
... With children going back to school, parents are concerned that ... who dine in a school cafeteria. New research funded ... eat school lunches that are part of the federal government,s ... The same research study found, however, that children who ...
... to locate and identify a gene responsible for a fatal ... may be responsible for a similar rare, fatal disease in ... of the disease in dogs and is the first step ... Dr. Natasha Olby, associate professor of neurology, was part ...
Cached Biology News:See amazing new sun images from NJIT's Big Bear Solar Observatory 2USDA-backed study finds federal school lunches linked to childhood obesity 2USDA-backed study finds federal school lunches linked to childhood obesity 3Researchers find gene responsible for neurodegenerative disease in dogs, possibly in humans 2
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: